BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 12176866)

  • 1. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.
    Couban S; Simpson DR; Barnett MJ; Bredeson C; Hubesch L; Howson-Jan K; Shore TB; Walker IR; Browett P; Messner HA; Panzarella T; Lipton JH;
    Blood; 2002 Sep; 100(5):1525-31. PubMed ID: 12176866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome.
    Woolfrey AE; Gooley TA; Sievers EL; Milner LA; Andrews RG; Walters M; Hoffmeister P; Hansen JA; Anasetti C; Bryant E; Appelbaum FR; Sanders JE
    Blood; 1998 Nov; 92(10):3546-56. PubMed ID: 9808546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
    Bensinger WI; Martin PJ; Storer B; Clift R; Forman SJ; Negrin R; Kashyap A; Flowers ME; Lilleby K; Chauncey TR; Storb R; Appelbaum FR
    N Engl J Med; 2001 Jan; 344(3):175-81. PubMed ID: 11172139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.
    Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A
    Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation.
    Mohty M; Bilger K; Jourdan E; Kuentz M; Michallet M; Bourhis JH; Milpied N; Sutton L; Jouet JP; Attal M; Bordigoni P; Cahn JY; Sadoun A; Ifrah N; Guyotat D; Faucher C; Fegueux N; Reiffers J; Maraninchi D; Blaise D
    Leukemia; 2003 May; 17(5):869-75. PubMed ID: 12750699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia.
    Schmitz N; Beksac M; Hasenclever D; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley JF; Gorin NC; Szer J; Bradstock K; Buzyn A; Clark P; Borkett K; Gratwohl A;
    Blood; 2002 Aug; 100(3):761-7. PubMed ID: 12130483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).
    Champlin RE; Schmitz N; Horowitz MM; Chapuis B; Chopra R; Cornelissen JJ; Gale RP; Goldman JM; Loberiza FR; Hertenstein B; Klein JP; Montserrat E; Zhang MJ; Ringdén O; Tomany SC; Rowlings PA; Van Hoef ME; Gratwohl A
    Blood; 2000 Jun; 95(12):3702-9. PubMed ID: 10845900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons between allogeneic peripheral blood stem cell transplantation and allogeneic bone marrow transplantation in adult hematologic disease: a single center experience.
    Liu YC; Chang CS; Liu TC; Chen TP; Sue YC; Hsiao HH; Lin SF
    Kaohsiung J Med Sci; 2003 Nov; 19(11):541-8. PubMed ID: 14658482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Less graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantation.
    Atta EH; de Oliveira DC; Bouzas LF; Nucci M; Abdelhay E
    PLoS One; 2014; 9(9):e107155. PubMed ID: 25188326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
    Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
    Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marrow versus blood-derived stem cell grafts for allogeneic transplantation from unrelated donors in patients with active myeloid leukemia or myelodysplasia.
    Bertz H; Spyridonidis A; Ihorst G; Engelhardt M; Grüllich C; Wäsch R; Marks R; Finke J
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):894-902. PubMed ID: 22108569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study.
    Couban S; Aljurf M; Lachance S; Walker I; Toze C; Rubinger M; Lipton JH; Lee SJ; Szer J; Doocey R; Lewis ID; Huebsch L; Howson-Jan K; Lalancette M; Almohareb F; Chaudhri N; Ivison S; Broady R; Levings M; Fairclough D; Devins G; Szwajcer D; Foley R; Smith C; Panzarella T; Kerr H; Kariminia A; Schultz KR
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1410-1415. PubMed ID: 27154847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
    Gupta V; Daly A; Lipton JH; Hasegawa W; Chun K; Kamel-Reid S; Tsang R; Yi QL; Minden M; Messner H; Kiss T
    Biol Blood Marrow Transplant; 2005 Oct; 11(10):764-72. PubMed ID: 16182177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.